Latest News of BGNE
Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE)
BeiGene faces challenges in its growth due to competition and regulatory factors. Despite financial gains, net losses persist. With a robust product pipeline and global presence, the company aims for ...
When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
BeiGene, Ltd., a leading oncology company, is progressing towards profitability with a projected breakeven in 2025. Analysts anticipate a profit of US$222m in 2026, expecting a 60% annual growth rate....
Insider Sale: CFO Julia Wang Sells Shares of BeiGene Ltd (BGNE)
Julia Wang, CFO of BeiGene Ltd, sold 899 shares at $155.66 each, owning 432,731 shares. The biotech company focuses on cancer treatments globally. Wang's recent sale raises interest due to insider beh...
-
BeiGene, Ltd. (NASDAQ:BGNE) Shares Could Be 47% Below Their Intrinsic Value Estimate
By Yahoo! Finance | 3 months agoThe intrinsic value of BeiGene, Ltd. (NASDAQ: BGNE) is estimated using the Discounted Cash Flow (DCF) model, resulting in a Total Equity Value of US$33b. This indicates the stock is currently underval...